CMT Research Foundation
VC Fund
CMT Research Foundation is a VC fund focused on Therapeutics and Biotechnology. The CMT Research Foundation is a patient-led non-profit dedicated to developing treatments and cures for Charcot-Marie-Tooth disease.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries CMT Research Foundation invests in
Stages CMT Research Foundation invests in
Countries CMT Research Foundation invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Patrick Livney
|
|||
Susan Ruediger
|
|||
Investment Focus
Industry
- Therapeutics 2 (33%)
- Biotechnology 2 (33%)
- Medical 1 (17%)
- Genetics 1 (17%)
- Biopharma 1 (17%)
Stage
- Series A 2 (33%)
- Seed 1 (17%)
- Grant 1 (17%)
- Venture - Series Unknown 1 (17%)
Country
- United States 2 (33%)
- Belgium 1 (17%)
- The Netherlands 1 (17%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Patrick Livney
Founder & Chair Emeritus CMT Research Foundation
|
Founder & Chair Emeritus CMT Research Foundation | Total investments: 0 | Find email | |
|
Susan Ruediger
Founder, Chief Mission Officer & Board Member
|
Founder, Chief Mission Officer & Board Member | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
XtRNA Bio
|
XtRNA Bio is developing a new class of RNA therapeutics targeting genetic diseases caused by translation defects. | Venture - Series Unknown / Jun 24, 2025 | |
Augustine Therapeutics
|
Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors and GABABR1a activators for the treatment of neurological diseases such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair. | $83.9M / Series A / Mar 24, 2025 | |
ReviR Therapeutics
|
ReviR Therapeutics is a genomics-based platform that develops novel medicines targeting human RNAs. | $30M / Series A / Jul 26, 2024 | |
|
Augustine Therapeutics
|
Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors and GABABR1a activators for the treatment of neurological diseases such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair. | $18.2M / Series A / Jun 26, 2024 | |
|
ReviR Therapeutics
|
ReviR Therapeutics is a genomics-based platform that develops novel medicines targeting human RNAs. | Grant / Jun 19, 2024 | |
First Atom Therapeutics
|
First Atom Therapeutics is an AI-integrated drug design company that leverages its proprietary PRISM™ Platform for the rational, atom-by-atom design of new medicines. Unlike traditional methods, its technology utilizes zero-shot AI that does not rely on existing chemical structures to develop new compounds. The company focuses on creatingbreakthrough, disease-modifying treatments for conditions with high unmet medical needs, including Amyotrophic Lateral Sclerosis (ALS), Parkinson’s Disease, and hereditary optic atrophies. | Seed |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does CMT Research Foundation invest in?
CMT Research Foundation invests primarily in Therapeutics, Biotechnology and Medical startups, most often at Series A and Seed stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact CMT Research Foundation?
Public channels for CMT Research Foundation include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at CMT Research Foundation?
The team at CMT Research Foundation includes Patrick Livney (Founder & Chair Emeritus CMT Research Foundation) and Susan Ruediger (Founder, Chief Mission Officer & Board Member). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
